Back to Treatments

Treatment

Daclatasvir + Sofosbuvir

1
Conditions
30
Trials
6,000
Participants
68%
Average Safety

Condition Evidence

Acute hepatitis C

30 trials · 6,000 participants

95% effectiveness · 68% safety
Daclatasvir + Sofosbuvir | DFDA